Reveals how KAT2B suppression of RAD51C improves olaparib sensitivity in colorectal cancer, suggesting new therapeutic strategies.
These results offer vital and novel insights into the combination of inhibitors in patients who are resistant to olaparib therapy, especially patients with RAD51C reversion mutations.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: